- Home
- » Tags
- » Velpatasvir
Top View
- Reseptregisteret 2014–2018 the Norwegian Prescription Database 2014–2018
- EPCLUSA (Sofosbuvir and Velpatasvir)
- GLASS Methodology for Surveillance of National Antimicrobial Consumption
- Sofosbuvir-Velpatasvir (Epclusa)
- Vosevi, Sofosbuvir/Velpatasvir/Voxilaprevir
- Clinical Policy: Sofosbuvir/Velpatasvir (Epclusa) Reference Number: ERX.SPMN.182 Effective Date: 10/16 Last Review Date: 09/16 Revision Log
- Sofosbuvir/Velpatasvir (Epclusa®) Drug Interactions a Quick Guide For
- Australian Public Assessment Report for Sofosbuvir / Velpatasvir / Voxilaprevir
- Treatment of HCV Genotype 3
- Treatment of HCV Genotype 2
- Olysio) Reference Number: CP.PHAR.280 Effective Date: 09.16 Last Review Date: 02.20 Line of Business: Medicaid Revision Log
- Managing Hepatitis C in Non-Dialysis Chronic Kidney Disease
- HEPATITIS C AGENTS Epclusa (Sofosbuvir & Velpatasvir), Harvoni
- Summary: Patients with HIV/HCV Coinfection from on September 24, 2021
- Elbasvir/Grazoprevir (Zepatier) Reference Number: CP.CPA.284 Effective Date: 11.01.16 Last Review Date: 08.21 Line of Business: Commercial Revision Log
- Sofosbuvir/Velpatasvir (Epclusa®) National Drug Monograph August
- VOSEVI® (Sofosbuvir, Velpatasvir, and Voxilaprevir) Tablets, for Voxilaprevir (3) Oral Use Initial U.S
- Sofosbuvir-Velpatasvir-Voxilaprevir (Vosevi)
- Sofosbuvir/Velpatasvir/Voxilaprevir (Vosevi) (CP.PCH.22)
- ATC-Index Mit DDD-Angaben Für Deutschland Im Jahre 2019
- (Epclusa)-Associated Photosensitivity in a Hepatitis C Patient: Case Report and Review of Photosensitivity to Hepatitis C Antiviral Agents
- Sofosbuvir/Velpatasvir for 12 Weeks in Hepatitis C Virus-Infected Patients with End-Stage Renal Disease Undergoing Dialysis
- Vosevi, INN-Sofosbuvir/Velpatasvir
- 208341Orig1s000
- Daklinza (Daclatasvir)
- Sofosbuvir/Velpatasvir Regimen Promises an Effective Pan-Genotypic Hepatitis C Virus Cure
- Olysio (Simeprevir)
- Genotype 1A – No Cirrhosis
- Sofosbuvir/Velpatasvir/Voxilaprevir (Vosevi®) Drug Interactions: A
- Epclusa Generic Name: Sofosbuvir and Velpatasvir Manufacturer5
- 5.01.606 Hepatitis C Antiviral Therapy
- Remdesivir from Wikipedia, the Free Encyclopedia
- Olysio (Simeprevir)
- Sofosbuvir/Velpatasvir (Epclusa) for Hepatitis C RANDI SOKOL, MD, MPH, Mmeded, Tufts University Family Medicine Residency Program, Malden, Massachusetts
- Ag-Atc-Beschluss-20171124.Pdf
- Grazoprevir/Elbasvir
- Treatment of HCV in Persons with HIV Coinfection
- Sofosbuvir/Velpatasvir for the Treatment of Hepatitis C Application for Inclusion on the WHO Model List of Essential Medicines (EML) Contents
- Identification of Novel Compounds Against Three Targets of SARS Cov-2 Coronavirus by Combined Virtual Screening and Supervised Machine Learning
- Hepatitis C Treatment Snapshot: Velpatasvir + Sofosbuvir
- Review of the Velpatasvir Patent Landscape: a Scoping Report
- Hepatitis C Medications Daklinza (Daclatasvir) Epclusa
- EPCLUSA and Ribavirin Combination Regimen Is Contraindicated in EPCLUSA Safely and Effectively
- Zepatier™ (Elbasvir / Grazoprevir)
- Genotype 1A – No Cirrhosis
- ESAC-Net Reporting Protocol 2018.Docx Introduction
- Drug Class Review Monograph – GPI Class 12 – Antivirals Review Time Frame: 02/2016 – 04/2017 Previous Class Review: 05/2016
- EPCLUSA® (Sofosbuvir and Velpatasvir) Gilead Sciences, Inc